Literature DB >> 8219866

Adjuvant chemotherapy in stage I breast cancer. More harm than benefit.

C B Mueller1.   

Abstract

Clinical trials of adjuvant chemotherapy for breast cancer have shown a prolonged disease-free interval but no improvement in survival. This review of the evidence indicates that adjuvant therapy induces an antineoplastic drug resistance that makes "salvage" therapy less effective. The benefit that is seen only in group statistics, not in an individual, must be weighed against the harm an individual incurs from the chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8219866      PMCID： PMC2379875     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


  12 in total

1.  Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.

Authors:  E G Mansour; R Gray; A H Shatila; C K Osborne; D C Tormey; K W Gilchrist; M R Cooper; G Falkson
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

2.  Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.

Authors:  C G Kardinal; M C Perry; A H Korzun; M A Rice; S Ginsberg; W C Wood
Journal:  Cancer       Date:  1988-02-01       Impact factor: 6.860

3.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

4.  Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.

Authors:  A Howell; H Bush; W D George; J M Howat; D Crowther; R A Sellwood; R D Rubens; J L Hayward; R D Bulbrook; I S Fentiman
Journal:  Lancet       Date:  1984-08-11       Impact factor: 79.321

5.  Stage II breast cancer is not simply a late stage I.

Authors:  C B Mueller
Journal:  Surgery       Date:  1988-10       Impact factor: 3.982

6.  Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer.

Authors:  B Fisher; E R Fisher; C Redmond
Journal:  J Clin Oncol       Date:  1986-06       Impact factor: 44.544

7.  Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.

Authors:  B E Hillner; T J Smith
Journal:  N Engl J Med       Date:  1991-01-17       Impact factor: 91.245

8.  A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.

Authors:  B Fisher; C Redmond; N V Dimitrov; D Bowman; S Legault-Poisson; D L Wickerham; N Wolmark; E R Fisher; R Margolese; C Sutherland
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

9.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

Authors:  B Fisher; J Costantino; C Redmond; R Poisson; D Bowman; J Couture; N V Dimitrov; N Wolmark; D L Wickerham; E R Fisher
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

10.  Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.

Authors:  P Valagussa; G Tancini; G Bonadonna
Journal:  Cancer       Date:  1986-10-01       Impact factor: 6.860
View more
  1 in total

1.  Debate on using adjuvant chemotherapy.

Authors:  M Levine
Journal:  Can Fam Physician       Date:  1994-02       Impact factor: 3.275
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.